Synairgen released further positive data from its lysyl oxidase-like 2 enzyme (LOXL2) inhibitor program to treat idiopathic pulmonary fibrosis (IPF), being conducted in collaboration with Pharmaxis. A Phase 1 clinical trial is set to start this year, if toxicology studies are successfully completed. Synairgen and Pharmaxis entered a collaboration in August…
Shorter telomeres — the DNA regions that protect the ends of chromosomes — are linked to lower survival rates in pulmonary fibrosis (PF) patients who receive a lung transplant. These patients’ lungs start failing sooner than those of other patients, suggesting that telomere length may be a factor to consider…
A molecular cascade that prompts stem cells used in lung transplants to drive fibrotic processes is responsible for the low survival rates of patients who obtain transplants, according to a study. The research also identified potential treatments to slow the fibrosis or scarring process. The good news is that is that the…
When patients with idiopathic pulmonary fibrosis (IPF) get involved in treatment decisions, it is likely to increase the dialogue between them and their doctors, according to a global survey supported by Boehringer Ingelheim. A key survey finding was that two of three IPF patients are involved in treatment decisions.
Researchers discovered a molecule that promotes lung fibrosis by integrating large amounts of data from patients, cell experiments, and animal models. They also used a big data approach to identify a potential treatment that targets the factor — a cancer therapy that is already in clinical trials. The study,…
A new Mayo Clinic study has demonstrated new evidence of the link between the biology of aging and idiopathic pulmonary fibrosis (IPF). The study, “Cellular senescence mediates fibrotic pulmonary disease,” appeared in this month’s issue of Nature Communications and point towards new possible directions for therapies targeting IPF. “Idiopathic pulmonary fibrosis…
Aeolus Pharmaceuticals has started a Phase 1 clinical trial to evaluate a new version of AEOL 10150 as a treatment for delayed effects of acute lung radiation exposure(Lung-ARS). The open-label, single-center Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics in healthy individuals of increasing doses of AEOL…
PBI-4050 is a safe and effective therapy for patients with idiopathic pulmonary fibrosis (IPF), according to results of the now-completed Phase 2 clinical trial developed by ProMetic Life Sciences. The open-label, single-arm, Phase 2 study (NCT02538536) enrolled 40 IPF patients at six different sites in Canada to investigate the safety,…
Lung cells of patients with idiopathic pulmonary fibrosis (IPF) have higher than normal levels of two cytokines, small proteins crucial to the functioning of the immune system, according to a study. The researchers also discovered higher than normal levels of the cytokines interleukin 33 (IL-33) and thymic stromal lymphopoietin (TSLP)…
People with idiopathic pulmonary fibrosis (IPF) who have low levels of oxygen in the blood (hypoxemia) might be closer to having a new treatment option with the launch of a Phase 1 trial evaluating GBT440 in healthy volunteers, and two Phase 2 tests in select IPF patients. Global Blood…
Get regular updates to your inbox.
